Overall Survival Benefit Update From RATIONALE-305

Opinion
Video

Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.

Video Player is loading.
Current Time 0:00
Duration 4:54
Loaded: 3.34%
Stream Type LIVE
Remaining Time 4:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay up to date on practice-changing data in community practice.